Lates News

On September 29th, Weicai and Bojian announced that their humanized anti-soluble amyloid beta (A) monoclonal antibody Lunkanai (trade name: Le Yibao) would be administered intravenously (IV) every four weeks as a maintenance dose regimen, and it has obtained approval from the China National Medical Products Administration (NMPA).